Waltham, MA, United States of America

Tyler Grebe

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Tyler Grebe

Introduction

Tyler Grebe is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of arginase inhibitors. With a total of 4 patents to his name, Grebe's work is paving the way for advancements in cancer treatment and respiratory inflammatory diseases.

Latest Patents

Among his latest patents, Grebe has disclosed compounds of formula (Ib) and (Ia), which are aimed at treating cancer and respiratory inflammatory diseases. These compounds, or their pharmaceutically acceptable salts, are designed to inhibit arginase, a key enzyme involved in various pathological conditions. The innovative methods of use for these compounds highlight their potential in pharmaceutical compositions, showcasing Grebe's commitment to addressing critical health issues.

Career Highlights

Tyler Grebe is currently employed at AstraZeneca AB, where he continues to contribute to groundbreaking research and development in the pharmaceutical industry. His work is characterized by a focus on creating effective treatments that can significantly improve patient outcomes.

Collaborations

Grebe collaborates with talented professionals in his field, including Scott Nathan Mlynarski and Sameer Pralhad Kawatkar. These partnerships enhance the innovative potential of his projects and contribute to the overall success of their research endeavors.

Conclusion

Tyler Grebe's contributions to the field of pharmaceuticals through his patents and collaborations are noteworthy. His work on arginase inhibitors represents a significant step forward in the treatment of serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…